Abstract
We investigated the relationships between metastasis-free interval (MFI) and tumor characteristics, and assessed the prognostic value of MFI for survival after metastasis in patients with metastatic breast cancer. Furthermore, we compared MFI among the subtypes. We identified 335 patients with postoperative tumor recurrence at distant site(s). All patients underwent curative resection and had a MFI of at least 6 months. MFI was categorized as short (<2 years), intermediate (≥2 years and <5 years), or long (≥5 years). Overall survival after metastasis (OSM) was estimated. Patients with a shorter MFI were younger, more likely to have initial metastasis to visceral organs, and had a larger tumor with a higher stage and grade as well as a higher rate of nodal involvement at initial diagnosis. Among 136 patients with known disease subtypes, shorter MFI was associated with the triple-negative subtype while longer MFI was associated with the hormone receptor-positive/human epidermal growth factor receptor 2 negative subtype. Mortality after metastasis declined sharply with increasing MFI up to approximately 2 years, and continued gradually declining between 2 and 5 years. An MFI longer than 5 years did not add any survival benefit. MF...Continue Reading
References
May 1, 1989·Statistics in Medicine·S Durrleman, R Simon
Feb 28, 1996·Statistics in Medicine·F E HarrellD B Mark
Oct 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T SaphnerR Gray
Mar 5, 1999·Breast Cancer Research and Treatment·S G HilsenbeckG M Clark
Oct 12, 1999·Breast Cancer Research and Treatment·A InsaJ Garcia-Conde
Dec 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M ColleoniC M Rudenstam
Jan 28, 2003·Cancer·Jenny ChangRichard M Elledge
Aug 14, 2003·British Journal of Cancer·J J JamesJ F R Robertson
Dec 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher B MoederUNKNOWN College of American Pathologists
Jul 22, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R LargillierE Chamorey
Oct 3, 2008·Breast Cancer Research and Treatment·James J DignamNorman Wolmark
Jan 27, 2011·The Oncologist·Naoki NiikuraRichard L Theriault
Oct 21, 2011·Cancer Investigation·E PlanchatJ M Nabholtz
Nov 1, 2011·Cancer Causes & Control : CCC·Su Yon JungJoel L Weissfeld
Nov 5, 2013·Nature Genetics·Weiyi ToySarat Chandarlapaty
Feb 11, 2014·The Lancet Oncology·Fabrice AndréHervé Bonnefoi
Apr 29, 2014·Breast Cancer Research and Treatment·A B G KwastS Siesling
Citations
Jun 19, 2016·The Breast : Official Journal of the European Society of Mastology·Jacques Bernier, Philip M P Poortmans
Aug 6, 2016·PloS One·Marie GossetJean-Guillaume Feron
Jan 20, 2017·Virchows Archiv : an International Journal of Pathology·István Artúr MolnárAnna-Mária Tőkés
Aug 5, 2017·PloS One·Margarite D MatossianMatthew E Burow
Apr 27, 2017·Scientific Reports·Hai-Yuan YangZhi-Ming Shao
Apr 25, 2018·The Breast Journal·Kelsey E LarsonStephanie A Valente
Oct 18, 2018·Breast Cancer Research and Treatment·Victoria SopikSteven A Narod
Aug 28, 2020·Frontiers in Oncology·Yujie LuKunwei Shen
Jan 23, 2021·The Breast Journal·Israel BarcoCarol Chabrera
Jul 24, 2021·JCO Clinical Cancer Informatics·Jeremy MasonJulia A Beaver
Aug 6, 2021·JCO Clinical Cancer Informatics·Carlos H BarcenasGabriel N Hortobagyi
Dec 21, 2019·The Lancet Oncology·Jennifer J GaoTatiana M Prowell
Nov 1, 2018·Biomedicine Hub·Elisa M SchunkertKurt Zänker